BioSpace News Archive

Gossamer Bio, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update.

Inspire Medical Systems, Inc., a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced that its management team will present at the KeyBanc Life Sciences and MedTech Investor Forum on Tuesday, March 19, 2024.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET.

Keros Therapeutics, Inc. announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 3:00 p.m. Eastern time.

INmune Bio, Inc., a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease reports significant improvements in electroencephalography, a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.

CervoMed Inc. announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies, demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB.

Avadel Pharmaceuticals plc announced today that members of management will participate in the following upcoming investor conferences.

NextCure, Inc. announced the publication of a manuscript titled “The FLRT3-UNC5B Checkpoint Pathway Inhibits T Cell-Based Cancer Immunotherapies” in the journal Science Advances, published by the American Association for the Advancement of Science.

Immutep Limited today announces safety and initial efficacy data from the first ever 90mg dosing of eftilagimod alpha (efti) in combination with weekly paclitaxel in patients from the safety lead-in (N=6) of the AIPAC-003 Phase II/III trial.

Nuvectis Pharma, Inc. today reported its financial results for the fiscal year 2023 and provided an update on recent business progress.